Bullboard - Stock Discussion Forum Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID... see more

Add To Watchlist

TSXV:CLAS.H - Post Discussion

Claritas Pharmaceuticals Inc > CLAS

View:

Post by mavericks2020 on Jul 14, 2021 9:32am

CLAS

Investors are shifting their correction investment strategies alongside market selloffs at large. A significant part of this strategy is to stay safe, calm, and diversified, but another key factor for many investors on the Stockhouse Bullboards is to gauge which companies will be able to recover, and when.

This week, we highlight two sides of the impact the markets have faced so far, by looking at the most-viewed companies in resources, as well as healthcare, specifically cannabis.

Starting with a look at what is happening in cannabis and the companies operating in and around that market, Kalytera Therapeutics Inc. (TSX-V:KLY, Forum) is now going by the name Claritas Pharmaceuticals, Inc. and this week, the CBD biotech company touted the potential of its proprietary nitric oxide releasing compound, R-107, as a therapy for coronavirus and COVID-19 infection, citing new data by Massachusetts General Hospital. Claritas has concentrated its focus on the development on R-107. The nitric oxide-releasing compound. Following administration orally in a capsule, or by nasal spray, or by injection, R-107 enters the bloodstream, where it slowly releases nitric oxide systemically over 24 hours.

242